Matthias is Vice President, Translational Programs and co-leads the investment team at UPMC Enterprises, the investment arm of UPMC, one of the largest integrated healthcare delivery and finance systems in the United States. Matthias and his team are focused on investing and incubating transformative scientific discoveries by partnering with entrepreneurs to identify the right target markets, exploring optimal business models, and helping teams find a clear development path for their innovative technologies. Prior to joining UPMC Enterprises Matthias was a Principal in L.E.K. Consulting’s Global Life Science Practice, supporting life sciences clients in the U.S., Europe, and Japan on market definition, business and portfolio planning and commercial strategy. Matthias completed a Ph.D. in cardiovascular and clinical pharmacology at the University of Cambridge (UK) and holds a doctorate in clinical veterinary medicine from Justus Liebig University in Giessen (GER).
This panel will discuss the status quo on VC investment in Cardiovascular Disease. Panelists will explore how new preclinical discovery paradigms, the use of personalized medicine approaches (i.e. biomarkers for patient stratification and trial acceleration) and novel therapeutic modalities could change the trajectory of VC investment in the Cardiovascular Space.